Yes, testosterone can cause gynecomastia (breast tissue growth in men). Between 10% and 25% of men on testosterone replacement therapy experience gynecomastia or breast pain as a side effect. The cause is not the testosterone itself but what your body does with it: an enzyme called aromatase converts a portion of testosterone into estradiol, a form of estrogen. When estrogen levels rise relative to testosterone, breast tissue can start to grow.
How Testosterone Converts to Estrogen
Your body naturally produces an enzyme called aromatase, found in fat tissue, the liver, and other organs. Aromatase takes testosterone and converts it into estradiol. This happens in all men at baseline, and it’s actually necessary for bone health and brain function. The problem starts when you introduce extra testosterone from an outside source. More testosterone in the system means more raw material for aromatase to work on, which can push estradiol levels higher than your body is used to.
What matters most isn’t the absolute level of estrogen but the ratio between testosterone and estradiol. Research suggests a beneficial testosterone-to-estradiol ratio falls between 10 and 30 (calculated as testosterone in ng/dL divided by estradiol in pg/mL). When that ratio tips too far toward estrogen, the risk of breast tissue changes goes up. Notably, in studies of drug-induced gynecomastia, hormonal profiles were within normal reference ranges in 81% of cases, meaning even “normal” estrogen levels can cause problems if the balance with testosterone is off.
Body Fat Makes It Worse
Fat tissue is one of the main sites where aromatase lives. The more body fat you carry, the more aromatase activity your body has, and the more testosterone gets converted to estradiol. This creates a feedback loop: higher estrogen promotes fat storage (particularly around the abdomen), which increases aromatase activity, which converts even more testosterone to estrogen and further suppresses your natural testosterone production. Men with significant excess body fat often start with lower testosterone and higher estradiol before they ever begin therapy, making them more susceptible to gynecomastia once exogenous testosterone is added.
Early Signs to Watch For
Gynecomastia doesn’t appear overnight. It typically starts with subtle changes that are easy to dismiss. The earliest and most common sign is increased nipple sensitivity, particularly when clothing rubs against them. This may progress to tenderness or mild pain in the breast area, followed by noticeable swelling of the tissue behind the nipple. In teenagers, pain is especially common.
More advanced signs include a firm or rubbery lump beneath the nipple, visible breast enlargement, and in rare cases, nipple discharge. If you notice dimpled skin on the breast or a hard, fixed lump, that warrants prompt medical evaluation, as these can indicate something other than gynecomastia.
Does Dosage Matter?
Higher doses generally mean higher risk, though the relationship isn’t perfectly linear. More testosterone gives aromatase more to convert, so supraphysiologic doses (the kind used in bodybuilding cycles) carry greater risk than standard replacement doses. But individual variation is significant. Some men aromatize heavily at modest doses, while others tolerate higher amounts without breast changes. Genetics, body composition, and how quickly your liver clears estrogen all play a role.
Studies on other medications show how dose-dependent gynecomastia can be. With spironolactone (a blood pressure drug known to cause breast growth), the prevalence of gynecomastia was 13% overall but jumped to 52% at daily doses above 150 mg. Testosterone follows a similar principle: the more you put in, the more estrogen you produce, and the higher the odds of breast tissue changes.
Can You Reverse It?
Timing is everything. Gynecomastia goes through two phases. The early phase involves active glandular proliferation, where breast tissue is soft and growing. During this window, reducing or adjusting the testosterone dose, lowering body fat, or using medication can shrink the tissue. The later phase involves fibrosis, where the tissue hardens and becomes scar-like. Once that happens, medication is far less effective and surgery becomes the primary option.
European clinical guidelines recommend a “watchful waiting” approach first: address the cause (adjust the dose, lose body fat, stop any other contributing substances) and see if the tissue regresses on its own. For cases that don’t resolve, two classes of medication are used. Selective estrogen receptor modulators (SERMs) like tamoxifen block estrogen from binding to breast tissue receptors. In studies, tamoxifen produced significant improvement in 74% to 95% of patients. Raloxifene, another SERM, achieved at least a 50% reduction in 86% to 93% of patients. Aromatase inhibitors take a different approach, blocking the enzyme that converts testosterone to estrogen in the first place, reducing overall estrogen production.
That said, the European Academy of Andrology does not recommend routine use of SERMs or aromatase inhibitors for gynecomastia management in general. These medications carry their own side effects, and the evidence supporting them, while promising, comes from a limited number of studies. For long-lasting gynecomastia that doesn’t respond to other interventions, surgery is considered the definitive treatment. The type and extent of the procedure depend on how much tissue and fat have accumulated.
Reducing Your Risk
The most practical steps involve controlling the factors that drive aromatization. Keeping body fat lower reduces the amount of aromatase enzyme available to convert testosterone. Using the lowest effective dose of testosterone limits how much substrate aromatase has to work with. Regular blood work tracking both testosterone and estradiol levels helps catch an imbalanced ratio before physical symptoms appear.
If you’re on TRT, paying attention to early signs like nipple sensitivity gives you the best window to intervene. Breast tissue changes caught in the first weeks to months are far easier to address than tissue that’s been growing for a year. The men who develop lasting gynecomastia are typically those who ignored early symptoms or ran high doses without monitoring their bloodwork.